CN104797578B - 作为TARP-γ8依赖性AMPA受体拮抗剂的6-((S)-1-{1-[5-(2-羟基-乙氧基)-吡啶-2-基]-1H-吡唑-3-基}-乙基)-3H-1,3-苯并噻唑-2-酮 - Google Patents

作为TARP-γ8依赖性AMPA受体拮抗剂的6-((S)-1-{1-[5-(2-羟基-乙氧基)-吡啶-2-基]-1H-吡唑-3-基}-乙基)-3H-1,3-苯并噻唑-2-酮 Download PDF

Info

Publication number
CN104797578B
CN104797578B CN201380061495.2A CN201380061495A CN104797578B CN 104797578 B CN104797578 B CN 104797578B CN 201380061495 A CN201380061495 A CN 201380061495A CN 104797578 B CN104797578 B CN 104797578B
Authority
CN
China
Prior art keywords
tarp
seizures
ethyl
compound
benzothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380061495.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104797578A (zh
Inventor
J.K.里尔
W.J.波特
J.M.威特金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104797578A publication Critical patent/CN104797578A/zh
Application granted granted Critical
Publication of CN104797578B publication Critical patent/CN104797578B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380061495.2A 2012-11-27 2013-11-20 作为TARP-γ8依赖性AMPA受体拮抗剂的6-((S)-1-{1-[5-(2-羟基-乙氧基)-吡啶-2-基]-1H-吡唑-3-基}-乙基)-3H-1,3-苯并噻唑-2-酮 Active CN104797578B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27
US61/730273 2012-11-27
PCT/US2013/070885 WO2014085153A1 (en) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist

Publications (2)

Publication Number Publication Date
CN104797578A CN104797578A (zh) 2015-07-22
CN104797578B true CN104797578B (zh) 2016-11-23

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061495.2A Active CN104797578B (zh) 2012-11-27 2013-11-20 作为TARP-γ8依赖性AMPA受体拮抗剂的6-((S)-1-{1-[5-(2-羟基-乙氧基)-吡啶-2-基]-1H-吡唑-3-基}-乙基)-3H-1,3-苯并噻唑-2-酮

Country Status (35)

Country Link
US (1) US8765960B2 (https=)
EP (1) EP2925754B1 (https=)
JP (1) JP6246227B2 (https=)
KR (1) KR101693133B1 (https=)
CN (1) CN104797578B (https=)
AP (1) AP2015008489A0 (https=)
AR (1) AR093527A1 (https=)
AU (1) AU2013352594B2 (https=)
BR (1) BR112015011200A2 (https=)
CA (1) CA2889243C (https=)
CL (1) CL2015001419A1 (https=)
CR (1) CR20150267A (https=)
CY (1) CY1118657T1 (https=)
DK (1) DK2925754T3 (https=)
DO (1) DOP2015000113A (https=)
EA (1) EA026686B1 (https=)
ES (1) ES2618260T3 (https=)
HR (1) HRP20170274T1 (https=)
HU (1) HUE033447T2 (https=)
IL (1) IL238831B (https=)
JO (1) JO3225B1 (https=)
MA (1) MA38126B1 (https=)
MX (1) MX356478B (https=)
MY (1) MY177721A (https=)
PE (1) PE20151728A1 (https=)
PH (1) PH12015501154B1 (https=)
PL (1) PL2925754T3 (https=)
PT (1) PT2925754T (https=)
SG (1) SG11201504164VA (https=)
SI (1) SI2925754T1 (https=)
TN (1) TN2015000200A1 (https=)
TW (2) TWI618705B (https=)
UA (1) UA114345C2 (https=)
WO (1) WO2014085153A1 (https=)
ZA (1) ZA201503733B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
KR20170141769A (ko) 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도
JP6804469B2 (ja) * 2015-04-29 2020-12-23 ヤンセン ファーマシューティカ エヌ．ベー． ベンゾイミダゾロン及びベンゾチアゾロン化合物並びにａｍｐａ受容体調節因子としてのそれらの使用
ES2865330T3 (es) 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
MX373652B (es) 2015-04-29 2020-04-02 Janssen Pharmaceutica Nv Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
JP6953527B2 (ja) * 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ．ベー． 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
RU2650523C1 (ru) 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1193968A (zh) * 1995-08-31 1998-09-23 诺瓦提斯公司 新的2,3－二氧－1,2,3,4－四氢－喹喔啉基衍生物
CN1436172A (zh) * 2000-06-12 2003-08-13 卫材株式会社 1,2－二氢吡啶化合物及其制备方法和用途
US20090170913A1 (en) * 2004-12-17 2009-07-02 James Peter Beck Novel mch receptor antagonists
WO2009123822A1 (en) * 2008-04-01 2009-10-08 Aircell, Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ａｍｐａ拮抗化合物の新規製造法
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
JP2012505198A (ja) * 2008-10-08 2012-03-01 ファイザー・インク Ｃｎｓ障害を治療する際にａｍｐａ調節剤として使用するためのテトラヒドロフラニルスルホンアミド
PE20120008A1 (es) * 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
EP2576544A4 (en) * 2010-06-01 2013-09-11 Angion Biomedica Corp INHIBITORS OF CYTOCHROMES P450 AND USES THEREOF
EP2694472B1 (en) * 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1193968A (zh) * 1995-08-31 1998-09-23 诺瓦提斯公司 新的2,3－二氧－1,2,3,4－四氢－喹喔啉基衍生物
CN1436172A (zh) * 2000-06-12 2003-08-13 卫材株式会社 1,2－二氢吡啶化合物及其制备方法和用途
CN1245386C (zh) * 2000-06-12 2006-03-15 卫材株式会社 1,2－二氢吡啶化合物及其制备方法和用途
US20090170913A1 (en) * 2004-12-17 2009-07-02 James Peter Beck Novel mch receptor antagonists
WO2009123822A1 (en) * 2008-04-01 2009-10-08 Aircell, Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network

Also Published As

Publication number Publication date
MX356478B (es) 2018-05-30
HK1209116A1 (en) 2016-03-24
EA201590823A1 (ru) 2015-08-31
JO3225B1 (ar) 2018-03-08
MA38126B1 (fr) 2017-11-30
PH12015501154A1 (en) 2015-08-10
WO2014085153A1 (en) 2014-06-05
CN104797578A (zh) 2015-07-22
KR101693133B1 (ko) 2017-01-04
AR093527A1 (es) 2015-06-10
DOP2015000113A (es) 2015-06-15
MX2015006697A (es) 2015-08-05
US8765960B2 (en) 2014-07-01
ZA201503733B (en) 2017-09-27
UA114345C2 (uk) 2017-05-25
HUE033447T2 (en) 2017-11-28
AU2013352594A1 (en) 2015-06-04
EA026686B1 (ru) 2017-05-31
ES2618260T3 (es) 2017-06-21
HRP20170274T1 (hr) 2017-04-07
US20140148441A1 (en) 2014-05-29
EP2925754B1 (en) 2016-12-28
IL238831B (en) 2018-08-30
PH12015501154B1 (en) 2018-05-30
AP2015008489A0 (en) 2015-05-31
JP2016501219A (ja) 2016-01-18
PT2925754T (pt) 2017-02-27
CA2889243A1 (en) 2014-06-05
TW201434834A (zh) 2014-09-16
BR112015011200A2 (pt) 2017-07-11
TN2015000200A1 (en) 2016-10-03
CL2015001419A1 (es) 2015-10-02
MY177721A (en) 2020-09-23
SI2925754T1 (sl) 2017-02-28
KR20150070401A (ko) 2015-06-24
CY1118657T1 (el) 2017-07-12
TWI618705B (zh) 2018-03-21
DK2925754T3 (en) 2017-02-20
IL238831A0 (en) 2015-06-30
SG11201504164VA (en) 2015-07-30
EP2925754A1 (en) 2015-10-07
PL2925754T3 (pl) 2017-07-31
WO2014085153A8 (en) 2014-07-31
CR20150267A (es) 2015-09-16
AU2013352594B2 (en) 2016-02-18
TW201825484A (zh) 2018-07-16
CA2889243C (en) 2017-06-13
MA38126A1 (fr) 2017-03-31
PE20151728A1 (es) 2015-12-02
JP6246227B2 (ja) 2017-12-13

Similar Documents

Publication Publication Date Title
CN104797578B (zh) 作为TARP-γ8依赖性AMPA受体拮抗剂的6-((S)-1-{1-[5-(2-羟基-乙氧基)-吡啶-2-基]-1H-吡唑-3-基}-乙基)-3H-1,3-苯并噻唑-2-酮
EP3625214B1 (en) Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
EP4346818B1 (en) Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
KR20200096261A (ko) 설폰아마이드 화합물 및 이의 용도
RU2735277C2 (ru) 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора
ES2443578T3 (es) Compuestos de tetrahidrotriazolopiridina como potenciadores de receptores selectivos de mGlu5 útiles para el tratamiento de la esquizofrenia
CN107530354A (zh) 使用syk抑制剂对慢性移植物抗宿主病的治疗
EP2897961B1 (en) Dihydropyrrolidino-pyrimidines as kinase inhibitors
MX2012009894A (es) Inhibidores dimericos de iap.
EP3204374B1 (en) Isoindoline derivatives
CA3213395A1 (en) Compositions and methods for treating polycythemia
WO2019241644A1 (en) Novel small molecule anticancer agents, combinations and uses thereof
US20100120803A1 (en) 3,4-dihydroquinazoline derivatives
US9403803B2 (en) Indole-3-carboxamides as kinase inhibitors
HK1209116B (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
WO2018181986A1 (ja) アダマンチルメチルアミン誘導体およびその医薬としての使用
HK40093043A (zh) GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant